Breaking News, Financial News

FibroBiologics Plans to Go Public

Secures $100 million capital commitment from GEM.

Author Image

By: Charlie Sternberg

Associate Editor

FibroBiologics, a clinical stage company developing fibroblast-based therapeutic cures for chronic diseases, has signed an agreement with GEM Global Yield LLC SCS (GEM), a private investment group, to provide FibroBiologics with up to $100 million over a 36-month term following a public listing of FibroBiologics common stock.    FibroBiologics will control the timing and maximum amount of the drawdown under this facility and has no minimum drawdown obligation. FibroBiologics will issue warrants ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters